ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

nerandomilast (16) vs tezepelumab (16)22 active2013–2031
nerandomilasttezepelumab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedTerminated
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
nerandomilast
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)P3
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)P3
CONQUESTP2
FIBRONEER™-ONP3
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)P2
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic DiseasesP3
MERCURION-IPFP3
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisP2
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisP3
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodP2
ARGiNAUTP2
NERAM-PFP4
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingP2
VERANDA™-SScP3
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)P3
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionP3
tezepelumab
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe AsthmaP2
NAVIGATORP3
DESTINATIONP3
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic DermatitisP2
DIRECTIONP3
COURSEP2
WAYPOINTP3
PASSAGEP4
WAYFINDERP3
CROSSINGP3
HORIZONP3
ARRIVALP3
EMBARKP3
JOURNEYP3
Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe AsthmaP3
TAPERP3

Upcoming readouts

21 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.